Article content

Health policy in Canada is not evidence-based. For proof, look no further than the new drug-price regulations being implemented by the federal government, and its ongoing consideration of a new public monopoly drug-insurance program known as Pharmacare. The cost of patented drugs is the phony excuse driving both.

The government recently announced new rules that will arbitrarily regulate a lower ceiling price for patented drugs — even though its own data show that current prices have grown slower than inflation, and are below the median of comparable countries.

We apologize, but this video has failed to load.

tap here to see other videos from our team. Try refreshing your browser, or How Ottawa's using a fake drug crisis to force through damaging pharmaceutical policy Back to video

Pharmacare is proposed as a federal program that would replace all employment-based drug benefits in both the private and public sector, as well as replacing existing federal, provincial and territorial government-run drug plans. This despite the fact that it would shift over $25 billion off the provinces and the private sector onto the federal budget, including more than $13 billion in new costs for taxpayers.